| Bioactivity | Elagolix is a highly potent, selective, orally-active, short-duration, non-peptide antagonist of the gonadotropin-releasing hormone receptor (GnRHR) (KD = 54 pM).Target: GnRHin vitro: Elagolix is a short-acting, nonpeptide, GnRH antagonist, administered orally, that unlike injectable depot GnRH agonists and antagonists, produces a dose-dependent suppression of ovarian estrogen production, that is, from partial suppression at lower doses to full suppression at higher doses. Elagolix is regarded as the frontrunner of a new class of GnRH inhibitors that have been denoted as second-generation, due to their non-peptide nature and oral bioavailability. | ||||||||||||
| Name | (R)-Elagolix | ||||||||||||
| CAS | 834153-87-6 | ||||||||||||
| Formula | C32H30F5N3O5 | ||||||||||||
| Molar Mass | 631.59 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Carr B, et al. Elagolix, an oral GnRH antagonist, versus subcutaneous depot medroxyprogesterone acetate for the treatment of endometriosis: effects on bone mineral density. Reprod Sci. 2014 Nov;21(11):1341-1351. |
(R)-Elagolix
CAS: 834153-87-6 F: C32H30F5N3O5 W: 631.59
Elagolix is a highly potent, selective, orally-active, short-duration, non-peptide antagonist of the gonadotropin-r
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.